Digest Network How does it work
Network
/
Society
Ce
Not verified

Celltrion

What we write about

BiotechnologyHealthIndustriaMedicine - variousPharmaceuticals

12 Press releases

View all press releases
25/02/2025
Scienza
Marketing
Communication
Medicine - various
Biotechnology
Sanità
Health
Pharmaceuticals
Industria
Celltrion riceve l'autorizzazione della CE per Avtozma® (CT-P47), un farmaco biosimilare di RoActemra® (tocilizumab)
Source
Celltrion
Issuer
Business Wire
1.00
0
23/02/2025
Scienza
Marketing
Communication
Medicine - various
Biotechnology
Sanità
Health
Pharmaceuticals
Industria
Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)
Source
Celltrion
Issuer
Business Wire
1.00
0
20/02/2025
Eventi
Industria
Biotechnology
Sanità
Health
Pharmaceuticals
Medicine - various
Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab
Source
Celltrion
Issuer
Business Wire
1.00
0
20/02/2025
Eventi
Industria
Biotechnology
Sanità
Health
Pharmaceuticals
Medicine - various
Celltrion presenta le nuove analisi post-hoc degli studi LIBERTY al 20º congresso ECCO, presentando un'ulteriore valutazione dell'efficacia e della sicurezza di infliximab in formulazione sottocutanea (SC)
Source
Celltrion
Issuer
Business Wire
1.00
0
18/10/2024
Eventi
Industria
Health
Sanità
Medicine - various
Pharmaceuticals
Biotechnology
Celltrion presenta i risultati dell'analisi post-hoc a 2 anni per l'infliximab sottocutaneo (CT-P13 SC), evidenziando l'incremento della dose come opzione per gestire la perdita di efficacia nella malattia infiammatoria intestinale
Source
Celltrion
Issuer
Business Wire
1.00
0
15/10/2024
Eventi
Industria
Health
Sanità
Medicine - various
Pharmaceuticals
Biotechnology
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
Source
Celltrion
Issuer
Business Wire
1.00
0
25/08/2024
Health
Sanità
Medicine - various
Pharmaceuticals
Biotechnology
Industria
La Commissione europea approva SteQeyma ® (CT-P43) di Celltrion, un biosimilare di Stelara® (ustekinumab), per il trattamento di diverse malattie infiammatorie croniche
Source
Celltrion
Issuer
Business Wire
1.00
0
25/08/2024
Health
Sanità
Medicine - various
Pharmaceuticals
Biotechnology
Industria
European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases
Source
Celltrion
Issuer
Business Wire
1.00
0
17/06/2024
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Eventi
Fairs
Industria
Celltrion presenta risultati promettenti all'EULAR 2024 nello studio di fase III per CT-P47, candidato biosimilare di RoActemra® (tocilizumab) in pazienti affetti da artrite reumatoide (AR)
Source
Celltrion
Issuer
Business Wire
1.00
0
13/06/2024
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Fairs
Eventi
Industria
Celltrion showcases promising results in phase III study for CT-P47, a biosimilar candidate of RoActemra® (tocilizumab) in patients with rheumatoid arthritis (RA) at EULAR 2024
Source
Celltrion
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0